Total number of diversity investments made by an investor, Total number of current team members an organization has on Crunchbase, Descriptive keyword for an Organization (e.g. Nos expertises nous permettent de proposer différentes stratégies d’investissement, notre but étant d’offrir … - andera Life Sciences He then worked in Private Equity at Andera Partners, within the Winch Capital team. ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV), today announced the close of a US $44 million Series C financing led by CR-CP Life Science Fund. About Us We are building and advancing a portfolio through global approval by establishing strong ties and collaborations with endocrinologists, the medical community at large and patient advocacy organizations ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV), today announced the close of a US $44 million Series C financing led by CR-CP Life Science Fund. - andera Life Sciences We also use third-party cookies that help us analyze and understand how you use this website. Preclinical tests demonstrated sisunatovir to have an excellent toxicity profile with an attractive therapeutic index. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. You also have the option to opt-out of these cookies. - andera Life Sciences Andera Partners will continue to raise funds in its current segments. RSV is a respiratory pathogen that can lead to severe and life-threatening lower respiratory tract infections (LRTIs) in high-risk populations, such as infants, immunocompromised patients, and the elderly. Founded by Baron Edmond de Rothschild in 1953, the Group has been chaired by his son, Baron Benjamin de Rothschild, since 1997. Bastien Gagnol Corporate Counsel 01 53 93 65 These cookies do not store any personal information. Andera Partners Globally, there are an estimated 33 million cases of RSV LRTI each year in children younger than five years of age, with about 3 million of them being hospitalized and approximately 60,000 dying each year from complications associated with the infection. - Press releases, 04.01.2021 The firm has a partnership Before joining eCAP, he was an M&A Analyst at Leuwen where he … The company’s lead product candidate, sisunatovir, is an orally administered fusion inhibitor currently being evaluated in two global Phase 2 clinical studies: one in a pediatric patient population and the other in an adult stem-cell transplant patient population. Additional investors participating in the financing include Andera Partners, Brace Pharma Capital, … - Press releases, 06.08.2020 Sisunatovir was recently granted Fast Track designation by the U.S. Food and Drug Administration (FDA). ReViral is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics, with an initial focus on the treatment of respiratory syncytial virus (RSV). It has backed nearly 500 companies over more than 45 years, creating market leaders around . Its activities are grouped around two major areas: The Group offers wealthy families, entrepreneurs, and large institutions a full range of solutions combining a culture of tailored solutions, stability, performance, and innovation. These cookies will be stored in your browser only with your consent. Necessary cookies are absolutely essential for the website to function properly. The Edmond de Rothschild Group’s offering is characterised by strong convictions, with the desire to guarantee to each of its customers: A unique, close relationship, underpinned by the know-how and the variety of expertise of a large international group; Autonomous, experienced teams, who anticipate economic trends and innovate to establish long-term performance; The recognised stability, strength, and independence of a family-owned financial group. About Sisunatovir In 2018, results from a Phase 2a challenge study in healthy adult volunteers were reported, in which sisunatovir produced statistically significant reductions in viral load and clinical symptoms. The Fund invests in leading life science companies that develop innovative drugs, cell therapies, medical devices and smart healthcare technologies. It has backed nearly 500 companies over more than 45 years, creating market leaders around . 02.03.2021 - Press releases, 02.04.2020 - Press releases, 28.08.2020 ReViral has recently initiated two international multicentre Phase 2 clinical studies of sisunatovir in pediatric and adult high-risk patient populations. Fax: +33 1 85 73 64 37. Sofinnova Partners seeks to invest as a lead or cornerstone investor in seed, start-ups, corporate spin-offs and late stage companies. - andera Life Sciences This list of organizations invested in by Andera Partners provides data on their funding history, investment activities, and acquisition trends. CR-CP Life Science Fund is a venture capital fund jointly sponsored by China Resources Group (“CR”) and Charoen Pokphand Group (“CP”) with initial AUM of $300 million contributed by CR, CP and other global life science investors. erytech ERYtech Pharma is a biopharmaceutical company, develops enzyme-based medicinal products for the oncology, hematology and immunology sectors. ase à Pais, Andea Patnes est une société de gestion agréée AMF et compose de 62 pesonnes, dont 40 pofessionnels de l’investissement. RSV constitutes a substantial disease burden. - andera Life Sciences About Respiratory Syncytial Virus (RSV) Since 2016 we have built a portfolio of 70 companies within our strategic focus on BioTech / HealthTech, Industry 4.0 and Electric Bunnink, The Netherlands, 16 July 2019 – AM-Pharma B.V. (‘AM-Pharma, the Company’), a clinical stage biopharmaceutical company, leading in the development of a treatment for acute kidney injury (AKI) with its innovative recombinant human Alkaline Phosphatase therapeutic (recAP) today announces that it has raised €116m [$133m] from a European syndicate of new and existing investors. Azafaros enters clinical stage with AZ-3102, an oral small molecule being developed for rare neurogenetic disorders Welcome to BioMedPartners, a leading … Etienne graduated from HEC Paris and also studied at … The firm seeks to invest in companies operating in … We are full of enthusiasm to work alongside Andera Partners for their expertise in this type of project, which makes them the partner of choice for the next stage of growth.” Laurent Tourtois and Sylvain Charignon , Associate Directors at Andrea Partners, comment: “We are glad to support Eric Petco and Sonia Levy-Odier in this new step. Both programs were discovered in-house and the company has retained worldwide development and commercialization rights. - Press releases. ActoMezz accompagne des PME françaises « smid caps » valorisées entre Auparavant, Delphine a travaillé chez Andera Partners, ex Edmond de Rothschild Investment Partners, à Paris en tant … - andera Life Sciences - Press reviews, 11.06.2020 Elle est About Andera Partners Created in 2001 as part of the Edmond de Rothschild Group, Andera Partners is a leader in investments in unlisted companies in France and internationally. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. Andera Partners is an AMF-accredited asset management company and has 60 employees, 40 of whom are investment professionals. In addition, the company has an N-protein replication inhibitor program in late preclinical development. - andera Life Sciences –Ends– For media and investor inquiries, please contact: ReViral Delphine joined NextStage AM in July 2019. Sofinnova Partners seeks to invest as a lead or cornerstone investor in seed, start-ups, corporate spin-offs and late stage companies. - andera Life Sciences Phone: +33 1 85 73 64 00 “We are delighted by the strong financial support from this leading syndicate of healthcare investors, and we welcome Jason to our Board”, “The proceeds from the financing will be used to support Phase 2 clinical development for sisunatovir, our wholly-owned fusion protein inhibitor, and to progress our N-protein replication inhibitor program into Phase 1.”, “We are pleased to invest in ReViral and support their work to develop and commercialize novel therapeutics to treat RSV, a major global health concern. The US-Based National Institute of Health (NIH) estimates that, globally, RSV affects approximately 64 million people and causes approximately 160,000 deaths each year. Previously, Delphine worked at Andera Partners, formerly Edmond de Rothschild Investment Partners, in Paris as Back-Office Manager. ActoMezz est l’équipe spécialisée en investissement mezzanine et en capital minoritaire d’Andera Partners, avec près de 700 M€ sous gestion. - andera Life Sciences Corvidia Therapeutics is a clinical stage company focused on the research, development and commercialization of transformative therapies for cardio-renal diseases. - andera Life Sciences Edmond de Rothschild Investment Partners, EdRIP, Edmon de Rothshild Group, Venture Capital Investors with Investments in Basel-Stadt, Early Stage Venture Investors with Investments in Oost-Vlaanderen. This website uses cookies to improve your experience while you navigate through the website. - Press releases. Andera Partners General Information Description Founded in 2001, Andera Partners is a private equity firm headquartered in Paris, France. Alan Musso, CFO Selling equity holders include former majority owner Cobepa and Andera Partners (formerly Edmond de Rothschild Investment Partners). Active, Closed, Alternate or previous names for the organization, Tags are labels assigned to organizations, which identify their belonging to a group with that shared label, This describes the type of investor this organization is (e.g. Etienne joined Andera Partners in August 2018 as an Analyst in the Andera MidCap team. Notes to Editors About ReViral. - Press releases, 06.05.2020 Currently, there are no effective therapeutic treatment options for patients who develop RSV infection. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. But opting out of some of these cookies may have an effect on your browsing experience. Reviral raises $44 million in Series C financing. It is mandatory to procure user consent prior to running these cookies on your website. Clearwater International has advised the shareholders of Groupe Panhard, a leading player in logistics real estate development, on the sale of a minority stake to private equity fund Andera Partners. About CR-CP Life Science Fund Investors NovaQuest Capital Management, Life Sciences Partners (LSP), BRV Capital Management, Andera Partners, H. I. G. BioHealth Partners, F-Prime, KB Investment Energy Vault cleantech early stage TI … Basée à Paris, Andera Partners est une société de gestion agréée AMF et composée de 55 personnes, dont 40 professionnels de l’investissement. Angel, Fund of Funds, Venture Capital), This describes the stage of investments made by this organization (e.g. Before joining us, Etienne worked in mergers and acquisitions at Mediobanca and in Private Equity at Ardian. Sofinnova Partners seeks to invest as a lead or cornerstone investor in seed, start-ups, corporate spin-offs and late stage companies. Andera Partners, formerly known as Edmond de Rothschild Investment Partners (EdRIP) As heir to the traditions and values that have ensured the success of the Rothschild family for 250 years, the Edmond de Rothschild Group has established itself over time as a leading player in European finance. Détenue à 100% par ses équipes, Andera Partners place le service aux entepeneus, et le espect des patenaies au cœu de ses p occupations. It has backed nearly 500 companies over more than 45 years, creating market leaders around Andera Partners : Acteur de référencement du Capital-Investissement. The investment secures substantial new funding to fuel the next stage of the Company’s Andera Partners is a private equity firm focused on early- and late-stage venture investments. Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It manages nearly €2.3 billion in investments in life sciences, growth and buyout capital and sponsorless mezzanine debt. 374 rue Saint Honoré - 75001 Paris Before joining eCAP, he was an M&A Analyst at Leuwen where he worked on various deals and fundraising operations. In Phase 1 clinical studies, sisunatovir achieved target exposure levels with no serious adverse events being reported. Andera Partners poursuit ses levées de fonds sur ses segments actuels. Additional investors participating in the financing include Andera Partners, Brace Pharma Capital, Green Sands Equity, New Leaf Venture Partners, Novo Holdings, OrbiMed Advisors, and Perceptive Advisors. Andera Partners is a private equity firm focused on early- and late-stage venture investments. T: +1 832 270 5447 Jason Zhou M.D., CEO and Managing Director of CR-CP Life Science Fund, joins the ReViral Board of Directors. Andera Partners est une société de gestion spécialisée dans le Private Equity. Sunbo Angel Partners is an early-stage VC for unique B2B deep-tech and deep-science startups. Home > News > Reviral raises $44 million in Series C financing, 28.08.2020 By using our site, you agree to our cookie policy. - Press releases, 07.01.2021 London & Research Triangle Park, N.C., August 25, 2020 – ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV), today announced the close of a US $44 million Series C financing led by CR-CP Life Science Fund. Most recently, he was Partner at Andera Partners, a Paris based venture capital and growth equity firm with over Î2 billion under management, focusing on life science investing. Angel, Fund of Funds, Venture Capital), General contact email for the organization. - andera Life Sciences Andera Partners is a private equity firm focused on early- and late-stage venture investments. €23m has been mainly provided by Cowen Healthcare Investments, a division of Cowen Investment Management, which joins the existing investor syndicate of LSP and Andera Partners, Forbion, Ysios Capital, Kurma Partners, ID Would you like more information on Andera Partners and its activities? This site uses cookies to establish statistics on its visitors. - Press releases, 23.07.2020 Andera Partners, a responsible and committed private equity company, creates the Andera Partners Foundation. - Press releases, 10.02.2021 - andera Life Sciences This category only includes cookies that ensures basic functionalities and security features of the website. - Press releases, 05.01.2021 We have confidence that ReViral’s world class management team, strong science, and deep clinical expertise will enable ReViral to become a leader in the RSV market.”. Delphine a rejoint NextStage AM en juillet 2019. - Press releases, 12.10.2020 By creating a foundation, Andera Partners is renewing its commitment to the non-profit sector and building on its CSR pledges. Andera Partners is a private equity firm focused on early- and late-stage venture investments. Sisunatovir is an orally administered fusion inhibitor designed to block RSV replication by inhibiting RSV F-mediated fusion of RSV with the host cell. Prior to that, he worked for Nomura Phase4 Ventures E: amusso@reviral.com - andera Life Sciences
Le Millénaire Aubervilliers, Marché De Lassurance Habitation, Job D'été 17 Ans, Où Envoyer Arrêt De Travail Cpam ?, Shenzhen Chine Carte, Jobteaser Career Center, Lettre De Motivation Gestionnaire Assurance Confirmé,